<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01657266</url>
  </required_header>
  <id_info>
    <org_study_id>SOPH155-0412/II</org_study_id>
    <nct_id>NCT01657266</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of PRO-155 Versus Nevanac in Post Phacoemulsification</brief_title>
  <official_title>Phase 2 Randomized, Double-blind Clinical Trial to Evaluate Efficacy and Safety of the Ophthalmic Solution PRO-155 Versus Nevanac 0.1% Ophthalmic Solution in Post Phacoemulsification Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Sophia S.A de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Sophia S.A de C.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy and safety of the ophthalmic solution
      PRO-155 in patients post phacoemulsification.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postsurgical inflammation is an inevitable condition after cataract surgery. The use of
      non-steroidal anti-inflammatory drugs is a safe option for treating ocular inflammation.

      This is a phase II randomized double-blind clinical trial. The aim is to compare and to
      evaluate efficacy and safety of two ophthalmic solutions in patients post
      phacoemulsification. Patients will be randomized to receive either PRO-155 or Nevanac for 60
      days.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cellularity in anterior chamber</measure>
    <time_frame>day 60</time_frame>
    <description>Change from Baseline in cellularity in anterior chamber after 60 days of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>flare in anterior chamber</measure>
    <time_frame>day 60</time_frame>
    <description>Change from Baseline in flare in anterior chamber after 60 days of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular pain</measure>
    <time_frame>day 60</time_frame>
    <description>Number of patients without pain, would be measured using the Visual Analog Pain Scale</description>
  </secondary_outcome>
  <other_outcome>
    <measure>fluorescein dye</measure>
    <time_frame>day 60</time_frame>
    <description>Number of patients with normal fluorescein dye</description>
  </other_outcome>
  <other_outcome>
    <measure>green lissamine dye</measure>
    <time_frame>day 60</time_frame>
    <description>Number of patients with normal green lissamine dye</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>PRO-155</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRO-155 ophthalmic solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nevanac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nepafenac Ophthalmic Solution 0.1%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO-155</intervention_name>
    <description>instill one drop 2 times a day (BID) for 30 days</description>
    <arm_group_label>PRO-155</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevanac</intervention_name>
    <description>instill one drop 2 times a day (BID) for 30 days</description>
    <arm_group_label>Nevanac</arm_group_label>
    <other_name>Nepafenac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18 years who require cataract surgery

          -  Both genders

          -  Provide informed consent

          -  Normal Laboratory results

        Exclusion Criteria:

          -  Patients with visual acuity of 20/40 or less in the contralateral eye of the surgery

          -  Patients with any trans-surgical complication

          -  Patients with a cataract &gt;NC4, C4 or P4 classified with the system LOCS

          -  Patients with any active corneal pathology

          -  Patients under any steroidal treatment (topic, systemic or inhaled)14 days prior
             surgery or NSAIDs 7 days before the surgery (except low-dose aspirin)

          -  Patients with IOP &lt;5 or &gt;21 mmHg

          -  Patients that have ocular pain, cellularity or flare at the moment of selection

          -  Patients with ocular exfoliation, trauma or any inflammatory disease

          -  Patients with diabetic retinopathy that need treatment or uncontrolled diabetes
             mellitus

          -  Patients who are planning cataract surgery of the contralateral eye 14 days after
             surgery of the study eye

          -  Patients with history of hypersensitivity or contraindication for any drug used in the
             study

          -  Patients under anticoagulant treatment

          -  Contact lens users

          -  Pregnant patients, at risk of pregnancy or breastfeeding

          -  Patients without birth control treatment

          -  Patients with any active toxicomanies (alcoholism, cigarette, cannabis or others)

          -  Patients who had participated in any clinical trial in the last 90 days

          -  Legal or mentally disabled patients who could not give informed consent

          -  Patients who cannot comply with all study requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Leopoldo M Baiza-Dur√°n, MD</last_name>
    <phone>+52(33) 30014200</phone>
    <phone_ext>1051</phone_ext>
    <email>lbaiza@sophia.com.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clotilde Ayala-Barajas, MSc</last_name>
    <phone>+52(33) 30014200</phone>
    <phone_ext>1074</phone_ext>
    <email>clotilde.ayala@sophia.com.mx</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Civil de Guadalajara Fray Antonio Alcalde</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raul Bustos, MD</last_name>
      <phone>36145501</phone>
      <phone_ext>121</phone_ext>
      <email>raulbustosz@yahoo.mx</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2012</study_first_submitted>
  <study_first_submitted_qc>August 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2012</study_first_posted>
  <last_update_submitted>May 19, 2014</last_update_submitted>
  <last_update_submitted_qc>May 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Nepafenac</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 14, 2016</submitted>
    <returned>July 22, 2016</returned>
    <submitted>May 29, 2017</submitted>
    <returned>December 29, 2017</returned>
    <submitted>February 8, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

